Chimeric antibody erbitux

Cetuximab (Erbitux) Chimeric antibody, IgGi EGFR Ligand competition ADCC CRC SSCHN... 

Chimeric or humanized monoclonal antibodies, and have the suffixes -ximab (chimeric antibodies that are about 65 percent human) or -zumab (humanized antibodies that are about 95 percent human). Getuximab (Erbitux) is a chimeric antibody that was approved by the FDA in 2004 for the treatment of colorectal, head, and neck cancers. Bevacizumab (Avastin) is a humanized antibody approved by the FDA in 2004 that shrinks tumors by preventing the growth of new blood vessels into them. 

Over the past decade, a wide variety of antibody-based targeting molecules have been assessed for their potential application in cancer therapy [200]. Monoclonal antibodies (mAb) were the first and are still the preferred class of targeting molecules. Current developments of antibodies have been focused on chimeric, humanized, and fully humanized derivatives to decrease their immunogenicity. Some of these antibody-based drugs have already undergone clinical development and have been successfully translated into the clinical environment. Such examples include rituximab (Rituxan ), trastuzumab (Herceptin ), cetuximab (Erbitux ), and bevacizumab (Avastin ). Rituximab was approved by the FDA for treating B-cell lymphoma in 1997. 

---